Trial reportJAMA network open2025
E-Health Intervention for Fear of Cancer Recurrence: A Randomized Clinical Trial.
Trial report in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04287218 (A Randomized Controlled Trial Comparing the Efficacy of Therapist Guided Internet-delivered Cognitive Therapy), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial Comparing the Efficacy of Therapist Guided Internet-delivered Cognitive Therapy (TG-iConquerFear) With Augmented Treatment as Usual in Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors
Who cites it
3 citing papers in PubMed.
- Overlap and distinction between fear of cancer recurrence and health anxiety in long-term colorectal cancer survivors.Journal of cancer survivorship : research and practice · 2026Article
- Validation of the fear of cancer recurrence inventory-short form in long-term colorectal cancer survivors.Journal of patient-reported outcomes · 2026Article
- Psychological resilience and fear of disease progression among hospitalized patients with unruptured intracranial aneurysms scheduled for endovascular intervention: implications for nursing practice.Frontiers in public health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Despite the availability of effective interventions, fear of cancer recurrence (FCR) remains a prevalent concern among cancer survivors, underscoring the need for approaches that balance accessibility (eg, an online program with asynchronous therapist guidance) with engagement and effectiveness. Objective: To evaluate the efficacy of a 10-week therapist-guided (TG) e-health intervention, TG-iConquerFear, to reduce FCR in colorectal cancer (CRC) survivors. Design, Setting, and Participants: This single-site, Danish population-based randomized clinical trial enrolled cancer-free adult CRC survivors aged 18 years or older from May 8, 2023, to April 8, 2024, with clinical FCR (FCR Inventory-Short Form [FCRI-SF] score ≥22). Eligible participants had completed curative-intent CRC treatment between March 1, 2014, and December 31, 2018. Follow-up was 6 months. Interventions: Participants were randomized 1:1 (stratified by age and sex) to receive TG-iConquerFear or augmented control. TG-iConquerFear comprised 6 modules with written therapist guidance delivered remotely, individually, and asynchronously as needed over 10 weeks. Augmented control was a diagnostic interview and referral to a webpage with self-help mindfulness exercises. Main Outcomes and Measures: The primary outcome was change in FCRI total score at 3 months postintervention, analyzed according to intention-to-treat. Results: Of 9946 eligible CRC survivors, 103 with clinically significant FCR were randomized. Prior to the intervention, 2 were excluded due to cancer and 6 dropped out. Of the remaining 95 participants (median age, 63 [IQR 57-72] years; 60 [63%] female; median time since diagnosis, 7 [IQR 6-9] years), 42 were analyzed in the TG-iConquerFear group and 53 in the augmented control group. Intervention participants completed a mean (SD) of 4.5 (1.9) of 6 modules. Total FCRI score decreased significantly from baseline to 3 months in the TG-iConquerFear group (mean change, -21.7 [95% CI, -30.1 to -13.3] points) but not in the control group (mean change, -2.6 [95% CI, -7.8 to 2.6] points). This represents a between-group difference of 19.1 (95% CI, 10.0-28.3) points (P < .001) and a standardized effect size (Cohen d) of 0.62 (95% CI, 0.13-1.10). A significantly higher proportion of TG-iConquerFear participants had FCRI-SF scores below the cutoff for clinical FCR at 3 months postintervention compared with self-help participants (22 of 27 [81%] vs 18 of 42 [43%]; P = .002). The number needed to treat was 3. Conclusions and Relevance: In this randomized clinical trial, TG-iConquerFear intervention participants reported a significant and clinically meaningful reduction in FCR compared with the control group, suggesting an e-health intervention may expand the range of FRC treatment options beyond face-to-face interventions. Trial Registration: ClinicalTrials.gov Identifier: NCT04287218.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.